The Next Evolution of T Cell Engagers in Oncology | Dr. Jack Silberstein - CEO, Deck Bio

For years, T cell therapies have transformed blood cancers - but solid tumors have remained one of the hardest problems in medicine. Now a new company called Deck Bio believes the issue isn’t just finding a better target...it’s that cancer may never have been a single-target disease in the first place.

Dr. Jack Silberstein, Ph.D. is the Founder and CEO of Deck Bio ( https://deck.bio/ ), a biotechnology company developing next-generation T cell engager therapies designed to address one of the most persistent challenges in solid tumor immunotherapy: antigen heterogeneity and immune escape.

Deck Bio’s platform takes a multi-target approach, engineering T cell receptors to simultaneously recognize multiple peptide-MHC (pMHC) complexes, with the goal of improving both tumor specificity and durable anti-tumor activity while reducing the on-target/off-tumor toxicity that has limited earlier T cell engager strategies.

Prior to founding Deck Bio, Dr. Silberstein trained as an immunology Ph.D. at Stanford University, where he was a Bio-X interdisciplinary fellow, and later worked at Johns Hopkins University on early clinical and translational oncology studies, including work on AR-V7 as a resistance biomarker in prostate cancer and early immune checkpoint combination trials. His background spans both deep immunology and real-world clinical translation in oncology.

Dr. Silberstein joins us following Deck Bio’s recent preclinical presentation at AACR 2026 in San Diego, where the company shared early data on its multi-pMHC targeting strategy.

#DeckBio #JackSilberstein #Immunotherapy #CancerResearch #TCellEngagers #Biotech #AACR2026 #SolidTumors #CancerTherapy #TCellTherapy #PrecisionMedicine #Oncology #TCRTherapy #CancerInnovation #Biotechnology #ImmuneSystem #CellTherapy #CancerBreakthrough #SyntheticBiology #FutureOfMedicine